Eliminating postnatal HIV transmission in high incidence areas: need for complementary biomedical interventions.
Anti-Retroviral Agents
/ therapeutic use
Breast Feeding
/ adverse effects
Female
HIV Infections
/ drug therapy
Health Policy
Health Services Accessibility
/ statistics & numerical data
Humans
Infant
Infant, Newborn
Infectious Disease Transmission, Vertical
/ prevention & control
Milk, Human
/ virology
Pregnancy
Pregnancy Complications, Infectious
/ drug therapy
Prenatal Care
/ methods
Journal
Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R
Informations de publication
Date de publication:
03 04 2021
03 04 2021
Historique:
received:
27
01
2020
revised:
06
06
2020
accepted:
02
10
2020
entrez:
4
4
2021
pubmed:
5
4
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
The rate of mother-to-child transmission (MTCT) of HIV from breastfeeding is increasing relative to other causes of MTCT. Early effective preconception and antenatal antiretroviral therapy (ART) reduces intrauterine and intrapartum MTCT, whereas maternal post-partum HIV acquisition, untreated maternal HIV, and suboptimal postnatal maternal ART adherence increase the risk of MTCT through breastfeeding. Although the absolute number of cases of MTCT acquired through breastfeeding is decreasing, the rate of decrease is less than the decrease in intrauterine and intrapartum MTCT. Unless current strategies are universally applied, they might not be sufficient to eliminate MTCT due to breastfeeding. Urgent action is needed to evaluate and implement additional preventive biomedical strategies in high HIV prevalence and incidence settings to eliminate MTCT from breastfeeding. Preventive strategies include: pre-exposure prophylaxis in breastfeeding women who have an increased risk of acquiring HIV; postnatal reinforcement strategies, such as maternal retesting for HIV, maternal care reinforcement, and prophylaxis in infants exposed to HIV via breastmilk; and active (vaccine) or passive immunoprophylaxis with long-acting broadly neutralising antibodies.
Identifiants
pubmed: 33812490
pii: S0140-6736(21)00570-5
doi: 10.1016/S0140-6736(21)00570-5
pii:
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1316-1324Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.